Exact Mass: 505.3767

Exact Mass Matches: 505.3767

Found 128 metabolites which its exact mass value is equals to given mass value 505.3767, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Mycinamicin VIII

Mycinamicin VIII

C29H47NO6 (505.3403)


   

LysoPC(P-18:1(9Z)/0:0)

(2-{[(2R)-2-hydroxy-3-[(1Z,9Z)-octadeca-1,9-dien-1-yloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C26H52NO6P (505.3532)


LysoPC(P-18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. LysoPC(P-18:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(P-18:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

3-[(19,20-dihydroxydocosa-4,7,10,13,16-pentaenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C29H47NO6 (505.3403)


(4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-19,20-dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Cholylproline

1-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanoyl)pyrrolidine-2-carboxylic acid

C29H47NO6 (505.3403)


Cholylproline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Cholylproline consists of the bile acid cholic acid conjugated to the amino acid Proline conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Cholylproline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Cholylproline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Chenodeoxycholylisoleucine

2-[(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-14-yl}-1-hydroxypentylidene)amino]-3-methylpentanoate

C30H51NO5 (505.3767)


Chenodeoxycholylisoleucine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylisoleucine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Isoleucine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylisoleucine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylisoleucine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Chenodeoxycholylleucine

2-(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)-4-methylpentanoic acid

C30H51NO5 (505.3767)


Chenodeoxycholylleucine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylleucine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Leucine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylleucine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylleucine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Deoxycholylisoleucine

2-(4-{5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)-3-methylpentanoic acid

C30H51NO5 (505.3767)


Deoxycholylisoleucine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylisoleucine consists of the bile acid deoxycholic acid conjugated to the amino acid Isoleucine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylisoleucine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylisoleucine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

C8 Ceramide-1-phosphate

C8 Ceramide-1-phosphate

C26H52NO6P (505.3532)


   

N-(20-amino-4,8-dihydroxy-4,8,12,17-tetraazaicosyl)-2-indole-3-acetamide

N-(20-amino-4,8-dihydroxy-4,8,12,17-tetraazaicosyl)-2-indole-3-acetamide

C26H47N7O3 (505.374)


   
   
   

Coumingin|N-Acetyl-coumingidin|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13seqtrans)]-essigsaeure-(2-dimethylamino-aethylester)|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13xi)]-essigsaeure-[2-(acetyl-methyl-amino)-aethylester]|[3beta-(beta-hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanylidene-(13seqtrans)]-acetic acid-(2-dimethylamino-ethyl ester)

Coumingin|N-Acetyl-coumingidin|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13seqtrans)]-essigsaeure-(2-dimethylamino-aethylester)|[3beta-(beta-Hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanyliden-(13xi)]-essigsaeure-[2-(acetyl-methyl-amino)-aethylester]|[3beta-(beta-hydroxy-isovaleryloxy)-7-oxo-14alpha-methyl-podocarpanylidene-(13seqtrans)]-acetic acid-(2-dimethylamino-ethyl ester)

C29H47NO6 (505.3403)


   

Agelenotoxin 505

Agelenotoxin 505

C26H47N7O3 (505.374)


   

anthcolorin C

anthcolorin C

C33H47NO3 (505.3556)


   

1-[2-(trans-1,4-dihydroxycyclohexyl)ethyl] 8-[(4R*,4aS*,6R*,7S*,7aR*)-2,4,7-trimethyloctahydro-1H-cyclopenta[c]pyridin-6-yl] (2E,6E)-2,6-dimethylocta-2,6-dienedioate|incarvine F

1-[2-(trans-1,4-dihydroxycyclohexyl)ethyl] 8-[(4R*,4aS*,6R*,7S*,7aR*)-2,4,7-trimethyloctahydro-1H-cyclopenta[c]pyridin-6-yl] (2E,6E)-2,6-dimethylocta-2,6-dienedioate|incarvine F

C29H47NO6 (505.3403)


   

N-(20-amino-4-hydroxy-4,8,12,17-tetraazaicosyl)-4-hydroxy-1H-indole-3-acetamide

N-(20-amino-4-hydroxy-4,8,12,17-tetraazaicosyl)-4-hydroxy-1H-indole-3-acetamide

C26H47N7O3 (505.374)


   

Leucine conjugated chenodeoxycholic acid

Leucine conjugated chenodeoxycholic acid

C30H51NO5 (505.3767)


   

Leucine conjugated chenodeoxycholic acid putative

Leucine conjugated chenodeoxycholic acid putative

C30H51NO5 (505.3767)


   

PC(O-18:2/0:0)[U]

3,5,9-Trioxa-4-phosphaheptacosa-18,21-dien-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-, inner salt, 4-oxide, (Z,Z)-(1)-

C26H52NO6P (505.3532)


   

LPC(p18:1)

1-(1Z,9Z-octadecadienyl)-sn-glycero-3-phosphocholine

C26H52NO6P (505.3532)


   

C-8 Ceramide-1-phosphate

N-octanoylsphingosine-1-phosphate

C26H52NO6P (505.3532)


   

21F121-A

1-(2,4,12-trimethyl-2E,5Z,7Z,9Z,11Z-hexadecapentaenoyl)-sn-glycero-3-O-(N,N,N-trimethyl)-homoserine

C29H47NO6 (505.3403)


   

LPC O-18:2

1-(1Z,9Z-octadecadienyl)-sn-glycero-3-phosphocholine

C26H52NO6P (505.3532)


   

C8 CerP

N-(octanoyl)-sphing-4-enine-1-phosphate

C26H52NO6P (505.3532)


   

N-octanoylsphingosine 1-phosphate

N-octanoylsphingosine 1-phosphate

C26H52NO6P (505.3532)


An N-acylsphingosine 1-phosphate in which the N-acyl group is specified as octanoyl.

   

Deoxycholylisoleucine

Deoxycholylisoleucine

C30H51NO5 (505.3767)


   

Chenodeoxycholylisoleucine

Chenodeoxycholylisoleucine

C30H51NO5 (505.3767)


   

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

(4Z,7Z,10Z,13Z,16Z)-19,20-Dihydroxydocosa-4,7,10,13,16-pentaenoylcarnitine

C29H47NO6 (505.3403)


   
   

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H52NO6P (505.3532)


   

HexCer 18:0;2O/2:0

HexCer 18:0;2O/2:0

C26H51NO8 (505.3614)


   

HexCer 8:0;2O/12:0

HexCer 8:0;2O/12:0

C26H51NO8 (505.3614)


   

HexCer 11:0;2O/9:0

HexCer 11:0;2O/9:0

C26H51NO8 (505.3614)


   

HexCer 9:0;2O/11:0

HexCer 9:0;2O/11:0

C26H51NO8 (505.3614)


   

HexCer 12:0;2O/8:0

HexCer 12:0;2O/8:0

C26H51NO8 (505.3614)


   

HexCer 14:0;2O/6:0

HexCer 14:0;2O/6:0

C26H51NO8 (505.3614)


   

HexCer 13:0;2O/7:0

HexCer 13:0;2O/7:0

C26H51NO8 (505.3614)


   

HexCer 17:0;2O/3:0

HexCer 17:0;2O/3:0

C26H51NO8 (505.3614)


   

HexCer 15:0;2O/5:0

HexCer 15:0;2O/5:0

C26H51NO8 (505.3614)


   

HexCer 16:0;2O/4:0

HexCer 16:0;2O/4:0

C26H51NO8 (505.3614)


   

NAGly 18:3/10:0

NAGly 18:3/10:0

C30H51NO5 (505.3767)


   

NAGly 12:0/16:3

NAGly 12:0/16:3

C30H51NO5 (505.3767)


   

NAGly 16:3/12:0

NAGly 16:3/12:0

C30H51NO5 (505.3767)


   

NAGly 10:0/18:3

NAGly 10:0/18:3

C30H51NO5 (505.3767)


   

2-aminoethyl [3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-hydroxypropyl] hydrogen phosphate

2-aminoethyl [3-[(11Z,14Z)-henicosa-11,14-dienoxy]-2-hydroxypropyl] hydrogen phosphate

C26H52NO6P (505.3532)


   

HexCer 10:0;2O/10:0

HexCer 10:0;2O/10:0

C26H51NO8 (505.3614)


   

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dodec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]decane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)tridec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxyhexadecanoylamino)dec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)undec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tridecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]tridecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]undecane-1-sulfonic acid

C26H51NO6S (505.3437)


   

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradec-4-ene-1-sulfonic acid

C26H51NO6S (505.3437)


   

2-(Hexadecanoylamino)-3-hydroxyundecane-1-sulfonic acid

2-(Hexadecanoylamino)-3-hydroxyundecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

2-(Dodecanoylamino)-3-hydroxypentadecane-1-sulfonic acid

2-(Dodecanoylamino)-3-hydroxypentadecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

2-(Decanoylamino)-3-hydroxyheptadecane-1-sulfonic acid

2-(Decanoylamino)-3-hydroxyheptadecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

3-Hydroxy-2-(tridecanoylamino)tetradecane-1-sulfonic acid

3-Hydroxy-2-(tridecanoylamino)tetradecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

3-Hydroxy-2-(undecanoylamino)hexadecane-1-sulfonic acid

3-Hydroxy-2-(undecanoylamino)hexadecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

3-Hydroxy-2-(tetradecanoylamino)tridecane-1-sulfonic acid

3-Hydroxy-2-(tetradecanoylamino)tridecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

2-(Heptadecanoylamino)-3-hydroxydecane-1-sulfonic acid

2-(Heptadecanoylamino)-3-hydroxydecane-1-sulfonic acid

C27H55NO5S (505.3801)


   

3-Hydroxy-2-(pentadecanoylamino)dodecane-1-sulfonic acid

3-Hydroxy-2-(pentadecanoylamino)dodecane-1-sulfonic acid

C27H55NO5S (505.3801)


   
   

N-(dodecanoyl)-4E-tetradecasphingenine-1-phosphate

N-(dodecanoyl)-4E-tetradecasphingenine-1-phosphate

C26H52NO6P (505.3532)


   

N-(decanoyl)-4E-hexadecasphingenine-1-phosphate

N-(decanoyl)-4E-hexadecasphingenine-1-phosphate

C26H52NO6P (505.3532)


   

Cer 18:3;2O/13:1;(3OH)

Cer 18:3;2O/13:1;(3OH)

C31H55NO4 (505.4131)


   

Cer 16:3;2O/15:1;(2OH)

Cer 16:3;2O/15:1;(2OH)

C31H55NO4 (505.4131)


   

Cer 19:3;2O/12:1;(2OH)

Cer 19:3;2O/12:1;(2OH)

C31H55NO4 (505.4131)


   

Cer 17:3;2O/14:1;(3OH)

Cer 17:3;2O/14:1;(3OH)

C31H55NO4 (505.4131)


   

Cer 16:3;2O/15:1;(3OH)

Cer 16:3;2O/15:1;(3OH)

C31H55NO4 (505.4131)


   

Cer 15:2;2O/16:2;(3OH)

Cer 15:2;2O/16:2;(3OH)

C31H55NO4 (505.4131)


   

Cer 15:3;2O/16:1;(3OH)

Cer 15:3;2O/16:1;(3OH)

C31H55NO4 (505.4131)


   

Cer 17:3;2O/14:1;(2OH)

Cer 17:3;2O/14:1;(2OH)

C31H55NO4 (505.4131)


   

Cer 15:3;2O/16:1;(2OH)

Cer 15:3;2O/16:1;(2OH)

C31H55NO4 (505.4131)


   

Cer 15:2;2O/16:2;(2OH)

Cer 15:2;2O/16:2;(2OH)

C31H55NO4 (505.4131)


   

Cer 18:3;2O/13:1;(2OH)

Cer 18:3;2O/13:1;(2OH)

C31H55NO4 (505.4131)


   

Cer 19:3;2O/12:1;(3OH)

Cer 19:3;2O/12:1;(3OH)

C31H55NO4 (505.4131)


   

cis-5-(6-(1,3-Dioxan-2-YL)hexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

cis-5-(6-(1,3-Dioxan-2-YL)hexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

C33H47NO3 (505.3556)


   

lysoDGTS 19:5

lysoDGTS 19:5

C29H47NO6 (505.3403)


   

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(octanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-acetamido-3-hydroxyoctadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-acetamido-3-hydroxyoctadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C25H50N2O6P+ (505.3406)


   

1-[(1Z,9Z)-octadecadienyl]-sn-glycero-3-phosphocholine

1-[(1Z,9Z)-octadecadienyl]-sn-glycero-3-phosphocholine

C26H52NO6P (505.3532)


A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphocholine in which the alkenyl group is (1Z,9Z)-octadecadienyl.

   

lysophosphatidylcholine P-18:1/0:0

lysophosphatidylcholine P-18:1/0:0

C26H52NO6P (505.3532)


A lysophosphatidylcholine P-18:1 in which the alkenyl group is located at position 1.

   
   
   
   
   

LPC P-18:1 or LPC O-18:2

LPC P-18:1 or LPC O-18:2

C26H52NO6P (505.3532)


   

CerP 14:1;O2/12:0

CerP 14:1;O2/12:0

C26H52NO6P (505.3532)


   

CerP 15:1;O2/11:0

CerP 15:1;O2/11:0

C26H52NO6P (505.3532)


   

CerP 16:1;O2/10:0

CerP 16:1;O2/10:0

C26H52NO6P (505.3532)


   

CerP 18:1;O2/8:0

CerP 18:1;O2/8:0

C26H52NO6P (505.3532)


   
   
   
   
   
   
   
   
   
   
   
   
   

ST 27:2;O4;Gly

ST 27:2;O4;Gly

C29H47NO6 (505.3403)


   

ST 28:1;O3;Gly

ST 28:1;O3;Gly

C30H51NO5 (505.3767)


   

ST 29:0;O2;Gly

ST 29:0;O2;Gly

C31H55NO4 (505.4131)


   

ST 21:1;O;HexNAc

ST 21:1;O;HexNAc

C29H47NO6 (505.3403)


   

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide

C33H47NO3 (505.3556)


   

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C33H47NO3 (505.3556)


   

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(4-hydroxy-1h-indol-3-yl)ethanimidic acid

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(4-hydroxy-1h-indol-3-yl)ethanimidic acid

C26H47N7O3 (505.374)


   

(3r)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3r)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3556)


   

7-{2-[2-(dimethylamino)ethoxy]-2-oxoethylidene}-1,1,4a,8-tetramethyl-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate

7-{2-[2-(dimethylamino)ethoxy]-2-oxoethylidene}-1,1,4a,8-tetramethyl-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate

C29H47NO6 (505.3403)


   

(3s)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3s)-3-{[(3s,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3556)


   

(3r)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3r)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3556)


   

n-{3-[(3-{[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl](hydroxy)amino}propyl)(hydroxy)amino]propyl}-2-(1h-indol-2-yl)ethanimidic acid

n-{3-[(3-{[3-({4-[(3-aminopropyl)amino]butyl}amino)propyl](hydroxy)amino}propyl)(hydroxy)amino]propyl}-2-(1h-indol-2-yl)ethanimidic acid

C26H47N7O3 (505.374)


   

(3e,5r,6r,7r,9r,11z,13e,15r,16r)-6-{[(2r,3s,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-3,11,13-triene-2,10-dione

(3e,5r,6r,7r,9r,11z,13e,15r,16r)-6-{[(2r,3s,4r,6s)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-16-ethyl-5,7,9,15-tetramethyl-1-oxacyclohexadeca-3,11,13-triene-2,10-dione

C29H47NO6 (505.3403)


   

(8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,8,10,12,14,16-hexamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C33H47NO3 (505.3556)


   

(3s)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

(3s)-3-{[(3r,4as,6as,8s,10ar,10bs)-3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3556)


   

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(4-hydroxy-1h-indol-2-yl)ethanimidic acid

n-[3-(17-amino-1-hydroxy-1,5,9,14-tetraazaheptadecan-1-yl)propyl]-2-(4-hydroxy-1h-indol-2-yl)ethanimidic acid

C26H47N7O3 (505.374)


   

3-{[3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

3-{[3-(2-hydroxypropan-2-yl)-6a,10b-dimethyl-7-methylidene-decahydronaphtho[2,1-b]pyran-8-yl]methyl}-1-(2-methylbut-3-en-2-yl)-3h-indol-2-one

C33H47NO3 (505.3556)